Rebound of clinical disease activity after fingolimod discontinuation? A nationwide cohort study of patients in Denmark.
Journal of neurology, neurosurgery, and psychiatry(2022)
摘要
Based on average ARR levels, there was no evidence of clinical rebound after fingolimod discontinuation. In total, 12.5% of patients had clinical rebound. Only 3.6%, however, had clinical rebound without disease activity before discontinuation. Disease activity before discontinuation, female sex and younger age were statistically significantly associated with a higher relapse risk after discontinuation.
更多查看译文
关键词
MULTIPLE SCLEROSIS,NEUROIMMUNOLOGY
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要